Calidi Biotherapeutics is an immunotherapy company based in San Diego. The company announced the exercise of warrants to generate gross proceeds. The press materials include a headline citing $2.1 million in gross proceeds while the article body reports $1.9 million. The financing instrument was the exercise of warrants; the articles do not disclose purchasers or participating investors. The announcement ran via Business Wire and was republished by Biotech Networks under the ticker $CLDI. Calidi Biotherapeutics is a clinical-stage immuno-oncology company based in San Diego, led by CEO Allan Camaisa. The company develops proprietary off-the-shelf, cell-based delivery platforms that protect, amplify, and potentiate oncolytic viruses to improve efficacy and patient safety. Its pipeline includes CLD-101, CLD-201, and CLD-202, which use a potent allogeneic stem cell and oncolytic virus combination for multiple oncology indications. Calidi’s technology focuses on effective delivery and potentiation of oncolytic viruses for targeted therapy against difficult-to-treat cancers. The company intends to use new funding to continue advancement of its pipeline programs. Financially, Calidi recently completed a $25M Series B financing to support its clinical development activities. Calidi Biotherapeutics is a clinical-stage immuno-oncology company developing cell-based oncolytic virus therapies. Its lead program, Supernova 1 (SNV1c), is a tumor-selective vaccinia virus combined with allogeneic adipose-derived mesenchymal stem cells (AD-MSC). The company is advancing a potent allogeneic stem cell and oncolytic virus combination for multiple oncology indications and is developing a universal cell delivery system to house, protect, and potentiate oncolytic viruses. The recently announced Series A investments from two South Korean firms will fund manufacturing work to prepare pre-IND and IND filings. Investment efforts were led by Heehyoung Lee, Ph.D., of LumeBio, who facilitated relationships with Won & Partners and Greentable Co., Ltd. Calidi is headquartered in San Diego, California.

Total raised

$27M

Funding rounds

3

Latest round

Equity

Latest activity

May 2024